Latest Period
Q4 2025
Security Snapshot
CASI Pharmaceuticals, Inc. - Ordinary Shares (CASIF) Institutional Ownership
CUSIP: G1933S101
13F Institutional Holders and Ownership History from Q4 2022 to Q4 2025
Institutions Reporting
16
Shares (Excl. Options)
1,251,879
Price
$0.85
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Ordinary Shares
- Symbol
- CASIF on OTC
- Shares outstanding
- 35,821,764
- Price per share
- $0.15
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 1,251,879
- Total reported value
- $1,063,851
- % of total 13F portfolios
- 0%
- Share change
- -1,354,964
- Value change
- -$2,036,507
- Number of holders
- 16
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- CASIF - CASI Pharmaceuticals, Inc. - Ordinary Shares is tracked under CUSIP G1933S101.
- 16 institutions reported positions in Q4 2025.
- 7 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 21 to 16 between Q3 2025 and Q4 2025.
- Reported value moved from $4,327,257 to $1,063,851.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 16 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP G1933S101?
CUSIP G1933S101 identifies CASIF - CASI Pharmaceuticals, Inc. - Ordinary Shares in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G1933S101:
Significant Owners of CASI Pharmaceuticals, Inc. - Ordinary Shares (CASIF) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| He Wei-Wu | 53% | +17% | $4,556,528 | +$1,204,800 | 18,985,535 | +36% | WEI-WU HE, Ph.D. | 23 Mar 2026 |
| Panacea Innovation Ltd | 22% | +13% | $4,698,042 | +$999,856 | 4,651,527 | +27% | James Huang | 16 Dec 2025 |
| Chen Zhenfeng M | 11% | $4,150,370 | 2,255,636 | Chen Zhenfeng | 30 Sep 2025 | |||
| Huang James | 14% | $3,177,509 | 2,161,571 | James Huang | 30 Jun 2025 | |||
| Venrock Healthcare Capital Partners III, L.P. | 9.2% | $2,066,749 | 1,987,259 | Venrock Healthcare Capital Partners III, L.P. | 31 Dec 2025 | |||
| SPARKLE BYTE LTD | 5% | $775,088 | 1,019,852 | SPARKLE BYTE LTD | 30 Sep 2025 | |||
| Ho Chi Sing | 4.8% | -27% | $754,405 | 992,638 | 0% | Zhou Quan | 30 Sep 2025 |
As of 31 Dec 2025, 16 institutional investors reported holding 1,251,879 shares of CASI Pharmaceuticals, Inc. - Ordinary Shares (CASIF). This represents 3.5% of the company’s total 35,821,764 outstanding shares.
Institutional Holders of CASI Pharmaceuticals, Inc. - Ordinary Shares (CASIF) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 1,251,879 | $1,063,851 | -$2,036,507 | $0.85 | 16 |
| 2025 Q3 | 2,606,843 | $4,327,257 | +$649,422 | $1.66 | 21 |
| 2025 Q2 | 2,245,168 | $2,648,852 | -$589,075 | $1.18 | 23 |
| 2025 Q1 | 2,744,278 | $5,927,688 | +$186,001 | $2.16 | 22 |
| 2024 Q4 | 2,658,168 | $7,523,090 | -$53,802 | $2.83 | 22 |
| 2024 Q3 | 1,322,529 | $8,138,853 | +$5,984,886 | $6.16 | 20 |
| 2024 Q2 | 352,170 | $1,936,256 | +$552,357 | $5.50 | 23 |
| 2024 Q1 | 252,002 | $909,576 | -$261,433 | $3.61 | 20 |
| 2023 Q4 | 275,894 | $1,981,066 | -$338,820 | $7.16 | 17 |
| 2023 Q3 | 344,608 | $882,628 | -$268,771 | $2.56 | 18 |
| 2023 Q2 | 449,838 | $1,124,376 | -$1,180,810 | $2.50 | 18 |
| 2023 Q1 | 929,752 | $2,152,582 | +$2,152,350 | $2.32 | 19 |
| 2022 Q4 | 100 | $179 | +$179 | $1.79 | 1 |